Posts tagged ‘GSK’

December 23, 2013

GlaxoSmithKline: le pharmacien qui lave plus blanc

Je n’ai rien fait mal, mais, je vous le promets, l’année prochaine j’arrête. » On pourrait résumer ainsi les bonnes résolutions annoncées à l’approche du Nouvel An par le groupe pharmaceutique britannique GlaxoSmithKline (GSK).

Il a toujours rejeté avec la plus grande énergie toutes les accusations de corruption des Etats-Unis jusqu’en Chine. Il annonce néanmoins une profonde refonte de ses méthodes commerciales. Il était innocent, il le sera encore plus !

Le laboratoire pharmaceutique a décidé d’arrêter de payer les médecins pour qu’ils prescrivent ses médicaments. Présenté lundi 16 décembre à ses cadres, ce plan de bonnes pratiques a été élaboré « pour [qu’ils restent] en phase avec la façon dont le monde est en train de changer», justifie Andrew Witty, le patron de GSK, dans une interview au New York Times.

Le britannique, dont les ventes se sont effondrées de 61 % au troisième trimestre en Chine, où une enquête pour corruption a été ouverte en juillet, propose rien de moins qu’une révolution.

GSK prévient qu’il va cesser de rémunérer les médecins et de leur offrir de luxueux voyages pour leurs interventions sur ses produits dans des conférences ou séminaires de formation. Il se trouve que dans le cadre de la réforme Obama sur la santé, toutes ces dépenses devront être publiées par les laboratoires en 2014. Le législateur américain a probablement joué ici le rôle d’aiguillon.

See on ecobusiness.blog.lemonde.fr

From Pharmaceutical Industry digital vision

Tags:
December 23, 2013

GSK to stop paying doctors in major marketing overhaul

(Reuters) – GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff – a first for an industry battling scandals over its sales practices, and a challenge for its peers to follow suit.

Britain’s biggest drugmaker also said on Tuesday it would stop payments to healthcare professionals for attending medical conferences as it tries to persuade critics it is addressing conflicts of interest that could put commercial interests ahead of the best outcome for patients.

The move may force other companies to act, since the entire drugs industry has been under fire for aggressive marketing tactics in recent years.

“Where GSK leads we must hope that other companies will follow,” Fiona Godlee, editor of the British Medical Journal and an influential campaigner against undue industry influence in medical practice, told Reuters.

“But there is a long way to go if we are to truly to extricate medicine from commercial influence. Doctors and their societies have been too ready to compromise themselves.”

GlaxoSmithKline’s move comes amid a major bribery investigation in China, where police have accused it of funneling up to 3 billion yuan ($494 million) to travel agencies to facilitate bribes to boost its drug sales.

However, the company said the measures were not directly related to its Chinese problems and were rather part of a broad effort to improve transparency.

See on www.reuters.com

From Pharmaceutical Industry digital vision

Tags:
December 15, 2013

GSK investing $330 million more in UK to increase output of new lung drug

The latest move will help it ramp up output of new lung drug Relvar, produce the long-established antibiotic Augmentin and develop innovative technologies for medicine production.

LONDON (Reuters) – GlaxoSmithKline is to invest another 200 million pounds ($330 million) on advanced manufacturing in Britain, the company said on Wednesday, underlining the draw of a tax break designed to encourage research and development.

Britain’s so-called “patent box” scheme, which offers a reduced rate of corporation tax on income derived from patents, has been hailed by GSK, its biggest drugmaker, for transforming the country as a place to invest.

Last year GSK announced it was building its first new factory in Britain for 40 years as a result of the scheme. The latest move will help it ramp up output of new lung drug Relvar, produce the long-established antibiotic Augmentin and develop innovative technologies for medicine production.

Britain’s health minister, Jeremy Hunt, welcomed the new investment. But not all Britain’s European partners are as enthusiastic about such patent box arrangements.

In July Germany called for a ban on these schemes, saying they created unfair competition. Patent boxes also operate in the Netherlands and some other European Union member states. ($1=0.6103 British pounds)

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

See on medcitynews.com

From Pharmaceutical Industry digital vision

Tags:
December 15, 2013

Patent box encourages GSK to invest $330 million more in UK

(Reuters) – GlaxoSmithKline is to invest another 200 million pounds ($330 million) on advanced manufacturing in Britain, the company said on Wednesday, underlining the draw of a tax break designed to encourage research and development.

Britain’s so-called “patent box” scheme, which offers a reduced rate of corporation tax on income derived from patents, has been hailed by GSK, its biggest drugmaker, for transforming the country as a place to invest.

Last year GSK announced it was building its first new factory in Britain for 40 years as a result of the scheme. The latest move will help it ramp up output of new lung drug Relvar, produce the long-established antibiotic Augmentin and develop innovative technologies for medicine production.

Britain’s health minister, Jeremy Hunt, welcomed the new investment. But not all Britain’s European partners are as enthusiastic about such patent box arrangements.

In July Germany called for a ban on these schemes, saying they created unfair competition. Patent boxes also operate in the Netherlands and some other European Union member states. ($1=0.6103 British pounds)

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

See on www.reuters.com

From Pharmaceutical Industry digital vision

Tags:
October 21, 2013

GSK va supprimer 271 postes en France

Un projet de réorganisation au sein de la filiale française du groupe pharmaceutique GSK a été présenté en comité central d’entreprise ce 21 octobre.

La filiale française du laboratoire pharmaceutique GSK va mettre en oeuvre une vaste réorganisation. Annoncé ce 21 octobre en Comité central d’entreprise, ce plan devrait avoir pour conséquence la suppression de 271 postes en France, selon les organisations syndicales. Dans le même temps, 49 postes seraient créés.

89 POSTES SUPPRIMÉS AU SIÈGE SOCIAL

Dans le détail, selon la CFE-CGC, 189 salariés sont concernés par le plan : 89 au siège social de Marly-le-Roy, 11 dans l’usine d’Evreux, 3 à Mayenne ainsi que 78 visiteurs médicaux. Le réseau de la force de vente devrait être profondément transformé par cette réorganisation, motivée par une prévision de perte de chiffre d’affaires d’ici 2016 , d’après la CFE-CGC.

Ce plan fait suite à l’annonce en février d’une vaste restructuration de la production et de la recherche de GSK à l’échelle européenne afin de restaurer sa compétitivité.

See on www.usinenouvelle.com

From Pharmaceutical Industry digital vision

Tags:
October 14, 2013

Paludisme: l’Alliance Gavi prudente sur le premier vaccin

L’Alliance Gavi (Alliance mondiale pour la vaccination, NDLR) va “garder un oeil” sur le premier vaccin contre le paludisme de GSK mais préfère attendre l’avis de l’OMS pour l’introduire dans ses campagnes de vaccination.

En novembre, “le Conseil d’administration (de Gavi) va discuter de ce vaccin”, a indiqué lundi aux médias à Genève, le directeur général de Gavi, Seth Berkley.
Il a expliqué que l’alliance Gavi, basée à Genève, allait “garder un oeil” sur ce nouveau vaccin, mais a-t-il souligné, aucune décision ne sera prise tant que l’Organisation mondiale de la santé (OMS) ne se sera pas prononcée sur ce vaccin.

La perspective de la commercialisation, d’ici à 2015, d’un premier vaccin contre le paludisme a été accueillie le 8 octobre avec intérêt mais prudence par les experts luttant contre cette maladie, responsable chaque année de quelque 660.000 morts en Afrique.
Le paludisme, aussi appelé malaria, tue essentiellement des enfants de moins de 5 ans et est l’une des maladies les plus meurtrières du continent.
Le groupe pharmaceutique britannique GSK, qui a développé le vaccin, doit encore solliciter le feu vert scientifique européen pour le vaccin antipaludéen destiné aux enfants d’Afrique subsaharienne.
D’après GSK, en cas de recommandation positive, l’OMS pourrait le recommander dès 2015, ce qui ouvrirait la voie à une diffusion en Afrique (principalement à travers l’Unicef et le programme humanitaire Gavi Alliance) à prix réduit, avec une marge de seulement 5%.
Gavi s’exprimait sur ce nouveau vaccin lors d’une conférence de presse destinée à présenter ses avancées en matière de vaccination. En 2011 et 2012, l’Alliance Gavi a ainsi immunisé environ 97 millions d’enfants contre différentes maladies dans les pays en développement. Cette année, quelque 48 millions d’enfants additionnels devraient aussi être immunisés.

See on www.leparisien.fr

From Pharmaceutical Industry digital vision

October 14, 2013

30 years in the making, GSK to seek European approval for first malaria vaccine – MedCity News

After trial data showed the shot significantly cut cases of the disease in African children, the drugmaker plans to seek marketing approval for the vaccine.

LONDON (Reuters) – British drugmaker GlaxoSmithKline will seek marketing approval for the world’s first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children.

The vaccine known as RTS,S was found, after 18 months of follow-up, to have almost halved the number of malaria cases in young children in the trial, and to have reduced by around a quarter the number of malaria cases in infants.

“Based on these data, GSK now intends to submit, in 2014, a regulatory application to the European Medicines Agency (EMA),” GSK, which has been developing the vaccine for three decades, said in a statement.

It added that the United Nations health agency, the Geneva-based World Health Organization (WHO), has indicated it may recommend use of the RTS,S vaccine from as early as 2015 if EMA drugs regulators back its licence application.

Malaria, a mosquito-borne parasitic disease, kills hundreds of thousands of people a year, mainly babies in the poorest parts of sub-Saharan Africa, and scientists say an effective vaccine is key to attempts to eradicate it.

Yet hopes that RTS,S would be the final answer were dampened last year when results from a final-stage trial with 6,537 babies aged six to 12 weeks showed the shot provided only modest protection, reducing episodes of the disease by 30 percent compared to immunisation with a control vaccine.

See on medcitynews.com

From Pharmaceutical Industry digital vision

Tags: ,
October 9, 2013

30 years in the making, GSK to seek European approval for first malaria vaccine – MedCity News

After trial data showed the shot significantly cut cases of the disease in African children, the drugmaker plans to seek marketing approval for the vaccine.

LONDON (Reuters) – British drugmaker GlaxoSmithKline will seek marketing approval for the world’s first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children.

The vaccine known as RTS,S was found, after 18 months of follow-up, to have almost halved the number of malaria cases in young children in the trial, and to have reduced by around a quarter the number of malaria cases in infants.

“Based on these data, GSK now intends to submit, in 2014, a regulatory application to the European Medicines Agency (EMA),” GSK, which has been developing the vaccine for three decades, said in a statement.

It added that the United Nations health agency, the Geneva-based World Health Organization (WHO), has indicated it may recommend use of the RTS,S vaccine from as early as 2015 if EMA drugs regulators back its licence application.

Malaria, a mosquito-borne parasitic disease, kills hundreds of thousands of people a year, mainly babies in the poorest parts of sub-Saharan Africa, and scientists say an effective vaccine is key to attempts to eradicate it.

See on medcitynews.com

From Pharmaceutical Industry digital vision

Tags: ,
August 25, 2013

GSK’s Crohn’s disease treatment fails in Phase III trial

LONDON (Reuters) – British pharmaceutical group GlaxoSmithKline Plc said vercirnon, a drug it was developing to treat Crohn’s disease and licensed from ChemoCentryx, had failed in a late-stage clinical trial.

The medicine, which GSK licensed from the California-based company in 2010, did not improve the incidence of adverse events in patients when measured against a placebo, GSK said on Friday, and there was a trend for overall adverse events to increase as dosage levels increased.

The trial failure wiped as much as $242 million, or nearly half, from ChemoCentryx’s value. Its shares were trading down 36 percent at $7.47 at 1438 GMT. GSK’s shares were up 0.3 percent at 1,672 pence, underperforming a 0.7 percent stronger FTSE 100 index.

See on news.yahoo.com

From Pharmaceutical Industry digital vision

Tags:
August 18, 2013

GSK launches £32m VC fund dedicated to bioelectronics (Wired UK)

GlaxoSmithKline is to launch a $50 million (£32m) strategic venture capital fund called Action Potential Venture Capital (APVC) that will invest in companies developing bioelectronics medicines and technologies…

GlaxoSmithKline is to launch a $50 million (£32m) strategic venture capital fund called Action Potential Venture Capital (APVC) that will invest in companies developing bioelectronics medicines and technologies.

GSK has been investing heavily in the field of bioelectronics, and established a dedicated Bioelectronics R&D unit in 2012. Wired.co.uk wrote about the initiative in May.

The fund has been named after electric signals called action potentials that pass along the body’s nerves. In a broad range of diseases, these electrical impulses can become irregular or disrupted in some way. We already have crude bioelectronic devices such as pacemakers, but more granular understanding and manipulation of neural pathways offer richer opportunities.

Tiny electronic devices can be designed to first of all map the electrical pathways through the body, and then modify or generate electronic impulses that can help to treat certain disorders instead of using drug-based interventions. The sorts of diseases that could benefit from bioelectronics include inflammatory diseases such as rheumatoid arthritis, respiratory diseases such as asthma, and type 2 diabetes. In the long run it might also be possible to control neuropsychiatric disorders like Parkinson’s and epilepsy.

See on www.wired.co.uk

From Pharmaceutical Industry digital vision